BiotechTube

Vesitirim™ (Solifenacin)

Pre-clinicalCompleted
2 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lower Urinary Tract Symptoms (LUTS)

Conditions

Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB)

Trial Timeline

Feb 1, 2012 → Dec 1, 2012

NCT ID
NCT01639794

About Vesitirim™ (Solifenacin)

Vesitirim™ (Solifenacin) is a pre-clinical stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms (LUTS). The current trial status is completed. This product is registered under clinical trial identifier NCT01639794. Target conditions include Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB).

What happened to similar drugs?

5 of 14 similar drugs in Lower Urinary Tract Symptoms (LUTS) were approved

Approved (5) Terminated (1) Active (8)
✅Tamsulosin + SolifenacinAstellas PharmaApproved
🔄tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
✅Tamsulosin + SolifenacinAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
🔄DuloxetineShionogiPhase 3
🔄Duloxetine + PlaceboShionogiPhase 3
🔄Nirsevimab + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01639794Pre-clinicalCompleted

Competing Products

20 competing products in Lower Urinary Tract Symptoms (LUTS)

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
11
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaPre-clinical
26
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaPhase 2
35
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
35
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
AZD1656AstraZenecaPhase 1
29
Nirsevimab + PlaceboAstraZenecaPhase 3
44
RSVpreF + PlaceboPfizerPhase 3
44
GabapentinPfizerApproved
43
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
30
ALX-0171 1.5 mg/kgSanofiPhase 2
27
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kgSanofiPhase 2
35
ALX-0171 Dose 1 + ALX-0171 Dose 2 + PlaceboSanofiPhase 2
27
Placebo + Hydrocodone bitartrateUCBPhase 3
40